Cytosorbents Corporation (CTSO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 39 | 40 | 35 | 31 | 36 | 37 | 37 | 39 |
| Operating profit | $m | -14 | -12 | ||||||
| Net profit | $m | -8 | -25 | -33 | -29 | -21 | -8 | -18 | -14 |
| EPS reported | $ | -0.13 | -5.75 | ||||||
| Operating cashflow per share | $ | -3.98 | -0.16 | ||||||
| Capex per share | $ | 0.05 | 0.00 | ||||||
| FCF per share | $ | -4.03 | -0.17 | ||||||
| Free cash flow | $m | -13 | -10 | ||||||
| Net debt | $m | 10 | 10 | ||||||
| Book value equity | $m | 6 | - | ||||||
| Book value per share | $ | 0.09 | -0.01 | ||||||
| Number of shares | m | 62.23 | 3.14 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.74 | -29.28 | ||||||
| P/S LTM | x | 1.07 | 1.07 | ||||||
| P/FCF LTM | x | -3.17 | -3.81 | ||||||
| EV/EBITDA LTM | x | -14.38 | -4.43 | ||||||
| EV/Sales LTM | x | 1.69 | 1.18 | ||||||
| Earnings Yield LTM | % | -20.62% | -82.83% | ||||||
| FCF Yield | % | -31.54% | -26.22% | ||||||
| Quality | |||||||||
| ROE | % | -138.88% | -445.14% | ||||||
| ROIC | % | -38.77% | -42.38% | ||||||
| Operating margin | % | -38.42% | -33.37% | ||||||
| Gross margin | % | +71.48% | +71.61% | ||||||
| FCF/Sales | % | -33.84% | -28.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +4.12% | +4.55% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.43 | -0.40 | ||||||
| Net Debt/EBITDA | x | -5.25 | -1.55 | ||||||
| EBIT/Net interest | x | -5.45 | -8.86 | ||||||
| Net debt/market cap | % | +41.91% | +1.20% | ||||||
| Net debt/Equity | x | 1.76 | - | ||||||
| Gross debt/equity | x | 4.93 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free